OrthoPediatrics (NASDAQ:KIDS) Shares Gap Up Following Analyst Upgrade

Shares of OrthoPediatrics Corp. (NASDAQ:KIDS) gapped up prior to trading on Tuesday after Truist Financial raised their price target on the stock from $35.00 to $38.00. The stock had previously closed at $33.60, but opened at $35.00. Truist Financial currently has a hold rating on the stock. OrthoPediatrics shares last traded at $35.44, with a volume of 160,769 shares trading hands.

Several other equities research analysts have also commented on KIDS. JMP Securities restated a “market outperform” rating and issued a $50.00 price objective on shares of OrthoPediatrics in a research report on Tuesday. Needham & Company LLC increased their price target on shares of OrthoPediatrics from $37.00 to $42.00 and gave the stock a “buy” rating in a report on Tuesday.

Insider Activity

In related news, CEO David R. Bailey sold 3,213 shares of OrthoPediatrics stock in a transaction on Monday, March 11th. The shares were sold at an average price of $27.59, for a total value of $88,646.67. Following the sale, the chief executive officer now owns 139,384 shares of the company’s stock, valued at approximately $3,845,604.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CFO Fred Hite sold 3,195 shares of OrthoPediatrics stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $27.59, for a total value of $88,150.05. Following the sale, the chief financial officer now directly owns 94,072 shares of the company’s stock, valued at $2,595,446.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO David R. Bailey sold 3,213 shares of the company’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $27.59, for a total transaction of $88,646.67. Following the sale, the chief executive officer now directly owns 139,384 shares of the company’s stock, valued at approximately $3,845,604.56. The disclosure for this sale can be found here. Insiders sold 17,253 shares of company stock worth $477,375 over the last three months. 31.80% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On OrthoPediatrics

A number of institutional investors and hedge funds have recently bought and sold shares of KIDS. CWM LLC boosted its position in shares of OrthoPediatrics by 16,283.3% during the 4th quarter. CWM LLC now owns 983 shares of the company’s stock valued at $32,000 after acquiring an additional 977 shares during the last quarter. RiverPark Advisors LLC acquired a new position in OrthoPediatrics in the 3rd quarter valued at about $35,000. International Assets Investment Management LLC grew its stake in shares of OrthoPediatrics by 3,151.4% in the 4th quarter. International Assets Investment Management LLC now owns 1,203 shares of the company’s stock valued at $37,000 after buying an additional 1,166 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of OrthoPediatrics by 136.3% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,341 shares of the company’s stock worth $107,000 after buying an additional 1,927 shares during the last quarter. Finally, Quantbot Technologies LP raised its position in shares of OrthoPediatrics by 180.8% during the 1st quarter. Quantbot Technologies LP now owns 7,091 shares of the company’s stock valued at $207,000 after buying an additional 4,566 shares during the period. 69.05% of the stock is currently owned by institutional investors and hedge funds.

OrthoPediatrics Trading Down 4.4 %

The stock has a market cap of $789.35 million, a PE ratio of -36.06 and a beta of 1.16. The company’s 50-day moving average price is $28.91 and its 200 day moving average price is $29.07. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.90 and a current ratio of 5.44.

OrthoPediatrics (NASDAQ:KIDS) last announced its quarterly earnings results on Wednesday, March 6th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.05. The business had revenue of $37.61 million for the quarter, compared to analyst estimates of $37.59 million. OrthoPediatrics had a negative return on equity of 5.03% and a negative net margin of 14.10%. On average, sell-side analysts forecast that OrthoPediatrics Corp. will post -1.34 EPS for the current fiscal year.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.